Biote Corp

BTMD

Market cap $42.6M

biote Corp. (BTMD) Q4 2025 Earnings Call Transcript

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago.

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. “Over the past twelve months, Biote has focused on our strategic priorities which are designed to drive sustainable profitable growth and create long-term value for stockholders,” said Bret Christensen, Biote's Chief.

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and healthy aging solutions, today announced the Company will provide fourth quarter and full year financial results on Wednesday, March 11, 2026, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conferenc.

biote Corp. ( BTMD ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bret Christensen - CEO & Director Robert Peterson - CFO and Chief Business Officer Conference Call Participants Szymon Serowiecki Kaumil Gajrawala - Jefferies LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Jeff Van Sinderen - B. Riley Securities, Inc., Research Division Jungwon Kim - TD Cowen, Research Division George Kelly - ROTH Capital Partners, LLC, Research Division Presentation Operator Good day, and welcome to the Biote Third Quarter 2025 Earnings Conference Call.

biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago.

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced financial results for the third quarter ended September 30, 2025. “When we undertook our organizational restructuring in May, we identified three strategic priorities: accelerate growth from new providers, maximize value from our top-tier clinics, and improve our financial performance through gre.

IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Wednesday, November 5, 2025, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call m.

I maintain my Strong Buy rating on biote Corp. due to its promising growth prospects, despite ongoing restructuring and short-term earnings pressure. The company's vertical integration, digital platform growth, and improved cost controls are driving margin expansion and long-term profitability potential. Restructuring aims to accelerate provider wins, deepen practitioner relationships, and boost financial discipline, though it has led to lower 2025 guidance.

biote Corp. (NASDAQ:BTMD ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bret Christensen - CEO & Director Robert C. Peterson - Chief Financial Officer Conference Call Participants Jeffrey Wallin Van Sinderen - B.